bcl-2 expression confers androgen independence in androgen sensitive prostatic carcinoma

International Journal of Oncology

Volumn 10, Issue 1, 1997, Pages 113-118

  Westin, Patrick ^a   Lo, Piao ^a   Marin, Maria C ^a   Fernandez, Antonio ^a   Sarkiss, Mona ^a   Tu, Shi Ming ^a   Brisbay, Shawn M ^a   Von Eschenbach, Andrew C ^a   McDonnell, Timothy J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Androgen ablation; Apoptosis; Bax; bcl 2; Prostate cancer

Indexed keywords

ANDROGEN; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTO ONCOGENE; RAT; TUMOR XENOGRAFT;

EID: 0031034951     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.1.113     Document Type: Article

References (28)

1. Boring CC, Squires TS, Tong T and Montgomery S: Cancer statistics. Cancer J Clin 44: 7-26, 1994.
2. Huggins C, Stevens REJ and Hodges CV: Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209-223, 1941.
3. Whitmore WF: Proceedings: the natural history of prostatic cancer. Cancer 32: 1104-1112, 1973.
4. Isaacs JT and Coffey DS: Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R3327H adenocarcinoma. Cancer Res 41: 5070-5075, 1981.
5. Bruchovsky N, Rennie PS, Goldman AJ, Goldenberg SL, To M and Lawson D: Control of tumor progression by maintenance of apoptosis. Cancer Res 50: 2275-2282, 1990.
6. Westin P, Bergh A and Damber J-E: Castration rapidly results in a major reduction in epithelial cell numbers in the rat prostate, but not in the highly differentiated Dunning R3327 prostatic adenocarcinoma. Prostate 22: 65-74, 1993.
7. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J-T, Tu S-M and Campbell ML: Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
8. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer SJ and Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993.
9. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB and Korsmeyer SJ: Multiple bcl-2 family members deonstrate selective dimerizations with bax. Proc Natl Acad Sci USA 92: 7834-7838, 1995.
10. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
11. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 74: 609-619, 1993.
12. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE and Oltvai ZN: Bcl-2/bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4: 327-332, 1993.
13. Williams GT: Programmed cell death: apoptosis and oncogenesis. Cell 65: 1097-1098, 1991.
14. McDonnell TJ: Cell division versus cell death: a functional model of multistep neoplasia. Mol Carcinogen 8: 209-213, 1993.
15. Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC and McDonnell TJ: Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 93: 147-155, 1995.
16. Humphries JE and Isaacs JT: Unusual androgen sensitivity of the androgen-independent Dunning R3327G rat prostatic adenocarcinoma: androgen effect on tumor cell loss. Cancer Res 42: 3148-3156, 1982.
17. Pollack A, Irvin GLI, Block NL, Lipton RM, Stover BJ and Claflin AJ: Hormone sensitivity of the R3327G rat prostate adenocarcinoma: growth rate, DNA content, and hormone receptors. Cancer Res 42: 2184-2190, 1982.
18. Pollack A, Bagwell CB, Block NL, Irvin GL, Claflin AJ and Stover BJ: Flow cytometric analysis of the R3327G rat prostatic adenocarcinoma to endocrine manipulation. J Surg Oncol 18: 389-398, 1981.
19. Gavrieli Y, Sherman Y and Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
20. Landberg G and Roos G: Antibodies to proliferating cell nuclear antigen as S-phase probes in flow cytometric cell cycle analysis. Cancer Res 51: 4570-4574, 1991.
21. Isaacs JT, Furuya Y and Berges R: The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 5: 391-400, 1994.
22. Kyprianou N and Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 12: 357-364, 1988.
23. Krajewski S, Krajewski M, Shabaik A, Miyashita T, Wang HG and Reed JC: Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of bcl-2. Am J Pathol 145: 1323-1336, 1994.
24. English HD, Kyprianou N and Isaacs JT: Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15: 233-251, 1989.
25. Kyprianou N, English HF and Isaacs JT: Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation. Cancer Res 50: 3748-3753, 1990.
26. Raffo AJ, Perlman H, Chen M-W, Day ML, Streitman JS and Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-4445, 1995.
27. Brandstrom A, Westin P, Bergh A, Cajander S and Damber J-E: Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Cancer Res 54: 3594-3601, 1994.
28. Westin P, Stattin P, Damber J-E and Bergh A: Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146: 1368-1375, 1995.